Author

C. Rudin

h-index 127 View on Semantic Scholar

We have 3 of 815 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study

Background In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended...

C. Rudin, M.-J. Ahn, M. Schuler et al. · Annals of Oncology · 0 citations

Open access Sep 2026

Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

It is shown that P-selectin is expressed by a subset of senescent-like cells in fibrotic tissues and tumors, which establishes SMNPs as a generalizable strategy to target pathogenic senescent cell subsets across fibrosis and cancer.

Clemens Hinterleitner, Valentin J. A. Barthet, Hailey V. Goldberg et al. · Science · 1 citation

Review Sep 2026

The changing therapeutic landscape of small-cell lung cancer.

Current standards of care, recent advances, and emerging approaches showing early promise for better management of SCLC are summarized and highlighted.

J. Ross, K. Hockemeyer, E. Redin et al. · The Lancet · 2 citations